Luna Kadouri

Summary

Affiliation: Hadassah University Hospital
Country: Israel

Publications

  1. doi request reprint Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations
    Luna Kadouri
    Sharett Institute of Oncology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel
    Breast Cancer Res Treat 140:207-11. 2013
  2. pmc A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers
    L Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    Br J Cancer 90:2002-5. 2004
  3. pmc Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers
    L Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    Br J Cancer 98:2006-10. 2008
  4. doi request reprint Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin
    Luna Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, 91120, Israel
    Fam Cancer 8:29-32. 2009
  5. ncbi request reprint Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers
    Luna Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    Int J Cancer 108:399-403. 2004
  6. pmc A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer
    Luna Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    BMC Cancer 7:14. 2007
  7. pmc Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations
    Hovav Nechushtan
    Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    BMC Cancer 9:60. 2009
  8. doi request reprint Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, POB 12000, Ein Kerem, Jerusalem, 91120, Israel
    Med Oncol 29:3035-8. 2012
  9. ncbi request reprint Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Ein Kerem, Jerusalem, Israel
    Cancer Biol Ther 12:165-8. 2011
  10. doi request reprint Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer
    Ayala Hubert
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, 91120 Jerusalem, Israel
    Fam Cancer 8:173-7. 2009

Collaborators

Detail Information

Publications18

  1. doi request reprint Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations
    Luna Kadouri
    Sharett Institute of Oncology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel
    Breast Cancer Res Treat 140:207-11. 2013
    ..Therefore, RAS is a rare event in BRCA carriers as in the general population, and should not be considered in the decision regarding irradiation treatment in this population. ..
  2. pmc A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers
    L Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    Br J Cancer 90:2002-5. 2004
    ..97; 95% CI 0.47-2.00). These results indicate significantly elevated risk for BC in carriers of BRCA2 mutations who also carry a RAD51-135c allele. In BRCA1 carriers and noncarriers, no effect for this SNP was found...
  3. pmc Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers
    L Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    Br J Cancer 98:2006-10. 2008
    ..The GSTM1- and GSTT1-null allele did not seem to have a major effect...
  4. doi request reprint Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin
    Luna Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, 91120, Israel
    Fam Cancer 8:29-32. 2009
    ..The Breast Cancer Linkage Consortium (BCLC) reported approximately 2.6-fold increase in the risk for CMM among BRCA2 carrier families...
  5. ncbi request reprint Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers
    Luna Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    Int J Cancer 108:399-403. 2004
    ..Longer repeat length correlates with elevated risk, whereas in carriers of a shorter AIB1 allele BC risk was reduced. The AIB1 polyglutamine length did not affect BC risk among BRCA2 mutation carriers...
  6. pmc A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer
    Luna Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    BMC Cancer 7:14. 2007
    ..But, the younger age of BC onset in Arab women compared with that of the Jewish population is suggestive of a genetic component in BC occurrence in that population...
  7. pmc Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations
    Hovav Nechushtan
    Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    BMC Cancer 9:60. 2009
    ..The differential effects of this SNP were also linked to estrogen receptor activation. Here we report on our study of 453 Ashkenazi breast cancer patients of whom 180 were positive for the known Ashkenazi BRCA1/2 mutations..
  8. doi request reprint Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, POB 12000, Ein Kerem, Jerusalem, 91120, Israel
    Med Oncol 29:3035-8. 2012
    ..302 and P = 0.707, respectively). In conclusion, long-term follow-up demonstrates that postoperative chemoradiation with combination of bolus 5-fluorouracil, continuous 5-fluorouracil, and cisplatin is a feasible approach...
  9. ncbi request reprint Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Ein Kerem, Jerusalem, Israel
    Cancer Biol Ther 12:165-8. 2011
    ..This may be applied also to other metastatic tumors diagnosed in BRCA1/2 carriers...
  10. doi request reprint Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer
    Ayala Hubert
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, 91120 Jerusalem, Israel
    Fam Cancer 8:173-7. 2009
    ..Tumors of BRCA2 carriers are resistant to chemotherapy, while the estrogen receptor positive nature of tumors results in better post recurrence survival...
  11. doi request reprint Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer
    Amir Sonnenblick
    Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Ein Kerem, P O Box 12000, Jerusalem, 91120, Israel
    Breast Cancer Res Treat 138:407-13. 2013
    ..Whether phospho-STAT3 has a predictive role of benefit from adjuvant chemotherapy has to be validated on prospective, randomized, controlled studies...
  12. doi request reprint Mutation spectrum in HNPCC in the Israeli population
    Yael Goldberg
    Sharret Institute of Oncology, Hadassah Hebrew University Medical Center, POB 12000, Kyriat Hadassah, 91120, Jerusalem, Israel
    Fam Cancer 7:309-17. 2008
    ..This is the first report that characterizes the profile of HNPCC in a cohort of patients in Israel. Tumor testing indicated that the 3 main MMR genes are involved, and that mutation spectrum is broad...
  13. doi request reprint The clinical effect of the inhibitor of apopotosis protein livin in melanoma
    Itay Lazar
    Department of Hematology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Oncology 82:197-204. 2012
    ..Livin binds caspases and thereby inhibits apoptosis. We found that caspases cleave livin to produce a truncated form with a paradoxical proapoptotic activity...
  14. pmc Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
    Michal Lotem
    Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Ein Karem Campus, 91120 Jerusalem, Israel
    J Immunol Res 2016:8121985. 2016
    ..007). Conclusion. Improved survival in patients attaining a strong DTH and increased response rate with subsequent ipilimumab suggests that the autologous vaccine confers protective immunity. ..
  15. doi request reprint Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells
    Michal Lotem
    Sharett Institute of Oncology and Departments of Surgery, Hadassah Hebrew University Hospital, Ein Karem and Mount Scopus Campuses, Jerusalem, Israel
    Clin Cancer Res 15:4968-77. 2009
    ..Survival data and immune response were evaluated in vaccinated patients...
  16. ncbi request reprint Preoperative radiotherapy and concurrent chemotherapy with bolus 5-fluorouracil for rectal cancer: a prospective analysis of 98 patients
    Marc Wygoda
    Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Tumori 96:709-12. 2010
    ..We here present the results of our combined-modality treatment protocol for patients with locally advanced rectal cancer...
  17. doi request reprint Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel
    Tamar Yablonski-Peretz
    Sharett Institute of Oncology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel
    Breast Cancer Res Treat 155:133-8. 2016
    ....
  18. ncbi request reprint Recurrent TP53 missense mutation in cancer patients of Arab descent
    Aviad Zick
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, 91120, Jerusalem, Israel
    Fam Cancer . 2016
    ..9%) of our selected BC patients. We suggest testing Arab women with a breast cancer at a young age, Arab patients with multiple malignancies, or with suggestive family history for TP53 c.541C>T...